SG11202009933WA - Bcl-2 INHIBITORS - Google Patents
Bcl-2 INHIBITORSInfo
- Publication number
- SG11202009933WA SG11202009933WA SG11202009933WA SG11202009933WA SG11202009933WA SG 11202009933W A SG11202009933W A SG 11202009933WA SG 11202009933W A SG11202009933W A SG 11202009933WA SG 11202009933W A SG11202009933W A SG 11202009933WA SG 11202009933W A SG11202009933W A SG 11202009933WA
- Authority
- SG
- Singapore
- Prior art keywords
- bcl
- inhibitors
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018085217 | 2018-04-29 | ||
| CN2018107134 | 2018-09-21 | ||
| PCT/CN2019/085001 WO2019210828A1 (en) | 2018-04-29 | 2019-04-29 | Bcl-2 INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009933WA true SG11202009933WA (en) | 2020-11-27 |
Family
ID=68386968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009933WA SG11202009933WA (en) | 2018-04-29 | 2019-04-29 | Bcl-2 INHIBITORS |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11420968B2 (en) |
| EP (1) | EP3788042A4 (en) |
| JP (1) | JP2021521138A (en) |
| KR (1) | KR20210005677A (en) |
| CN (3) | CN117430601A (en) |
| AU (1) | AU2019264475A1 (en) |
| BR (1) | BR112020022092A2 (en) |
| CA (1) | CA3098348A1 (en) |
| MX (2) | MX2020011495A (en) |
| SG (1) | SG11202009933WA (en) |
| TW (1) | TW202043217A (en) |
| WO (1) | WO2019210828A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018127130A1 (en) | 2017-01-07 | 2018-07-12 | Shanghai Fochon Pharmaceutical Co., Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| ES2927182T3 (en) | 2017-04-18 | 2022-11-03 | Shanghai Fochon Pharmaceutical Co Ltd | Apoptosis-inducing agents |
| NZ765825A (en) | 2018-01-10 | 2023-12-22 | Recurium Ip Holdings Llc | Benzamide compounds |
| BR112020022092A2 (en) | 2018-04-29 | 2021-02-02 | Beigene, Ltd. | compounds, method for treating unregulated apoptotic diseases and pharmaceutical composition |
| US20220073513A1 (en) | 2018-12-29 | 2022-03-10 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| US20230002369A1 (en) * | 2019-10-28 | 2023-01-05 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| CA3160417A1 (en) | 2019-12-06 | 2021-06-10 | Loxo Oncology, Inc. | Dosing of a bruton's tyrosine kinase inhibitor |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| EP4136084A4 (en) * | 2020-04-15 | 2023-11-01 | BeiGene, Ltd. | Bcl-2 inhibitor |
| US20230159527A1 (en) * | 2020-05-08 | 2023-05-25 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| CN114478520A (en) * | 2020-10-28 | 2022-05-13 | 杭州和正医药有限公司 | Bcl-2 protein apoptosis inducer and application thereof |
| CN117642157A (en) * | 2021-03-19 | 2024-03-01 | 伊尔治疗学股份有限公司 | Compounds having ((3-nitrophenyl) sulfonyl) acetamide as BCL-2 inhibitors |
| CN117616023A (en) * | 2021-04-13 | 2024-02-27 | 爱新医药科技(香港)有限公司 | BCL-2 or BCL-2/BCL-XL modulators and uses thereof |
| IL308931A (en) * | 2021-06-02 | 2024-01-01 | Beigene Switzerland Gmbh | Methods of treating b-cell malignancy using bcl-2 inhibitor |
| CN115490708A (en) * | 2021-06-18 | 2022-12-20 | 苏州亚盛药业有限公司 | Sulfonamide macrocyclic derivatives, and preparation method and application thereof |
| WO2023030363A1 (en) * | 2021-08-31 | 2023-03-09 | Beigene, Ltd. | Solid forms of bcl-2 inhibitors, method of preparation, and use thereof |
| WO2023078398A1 (en) * | 2021-11-05 | 2023-05-11 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| WO2023088167A1 (en) * | 2021-11-20 | 2023-05-25 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| WO2023104043A1 (en) * | 2021-12-06 | 2023-06-15 | 杭州和正医药有限公司 | Anti-apoptotic protein bcl-2 inhibitor, pharmaceutical composition and uses thereof |
| TW202400163A (en) | 2022-05-12 | 2024-01-01 | 英屬開曼群島商百濟神州有限公司 | Methods of treating myeloid malignancies using bcl-2 inhibitor |
| WO2023231777A1 (en) * | 2022-06-01 | 2023-12-07 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| WO2024017354A1 (en) * | 2022-07-21 | 2024-01-25 | Beigene, Ltd. | Methods of treating multiple myeloma using bcl-2 inhibitor |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| AR031130A1 (en) * | 2000-09-20 | 2003-09-10 | Abbott Lab | PROMOTING N-ACILSULFONAMIDS OF APOPTOSIS |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| CA2577752A1 (en) | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| DK1888550T3 (en) | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosis promoters |
| JP5147688B2 (en) | 2005-05-24 | 2013-02-20 | アボット・ラボラトリーズ | Apoptosis promoter |
| WO2008030836A2 (en) | 2006-09-05 | 2008-03-13 | Abbott Laboratories | Bcl inhibitors treating platelet excess |
| WO2009036051A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors containing a zinc binding moiety |
| CN102112445B (en) | 2008-06-09 | 2014-06-18 | 百时美施贵宝公司 | Hydroxyphenylsulfonamides as antiapoptotic Bcl inhibitors |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| UA108193C2 (en) | 2008-12-04 | 2015-04-10 | APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES | |
| RU2497822C2 (en) | 2008-12-05 | 2013-11-10 | Эббви Инк. | Blc-2 selective agents causing apoptosis for treating cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| JP5736318B2 (en) | 2008-12-08 | 2015-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Compounds for treating cancer |
| MX2011007681A (en) | 2009-01-19 | 2011-08-08 | Abbott Lab | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases. |
| MX2011007684A (en) | 2009-01-19 | 2011-08-08 | Abbott Lab | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases. |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2010138588A2 (en) * | 2009-05-26 | 2010-12-02 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CA2772989A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer |
| RS54388B1 (en) | 2010-03-25 | 2016-04-28 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (en) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI535712B (en) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | Chemical compounds |
| WO2012058392A1 (en) | 2010-10-29 | 2012-05-03 | Abbott Laboratories | Solid dispersions containing an apoptosis-inducing agent |
| IT1403156B1 (en) * | 2010-12-01 | 2013-10-04 | Università Degli Studi Di Torino | PHOSPHATIDYLINOSITOL 3-CHINASE INHIBITORS, RELATED COMPOSITIONS AND USES. |
| EP3459945A1 (en) | 2011-01-25 | 2019-03-27 | The Regents of The University of Michigan | Bcl-2/bcl-xl inhibitors for use in the treatment of cancer |
| US9346795B2 (en) | 2011-05-25 | 2016-05-24 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors |
| US8946445B2 (en) | 2011-10-12 | 2015-02-03 | Nanjing Allgen Pharma Co., Ltd. | Heterocyclic molecules as apoptosis inducers |
| KR20140107578A (en) | 2011-12-23 | 2014-09-04 | 노파르티스 아게 | Compounds for inhibiting the interaction of bcl2 with binding partners |
| WO2013096059A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| US20140357633A1 (en) | 2011-12-23 | 2014-12-04 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| MX2014007732A (en) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners. |
| WO2013096049A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| WO2013185202A1 (en) | 2012-06-14 | 2013-12-19 | Beta Pharma Canada Inc | Apoptosis inducers |
| ES2819232T3 (en) | 2013-01-16 | 2021-04-15 | Univ Michigan Regents | Bcl-2 / Bcl-xL inhibitors and their use in the treatment of cancer |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20190225607A1 (en) | 2016-07-06 | 2019-07-25 | Concert Pharmaceuticals, Inc. | Deuterated Venetoclax |
| WO2018027097A1 (en) | 2016-08-05 | 2018-02-08 | The Regents Of The University Of Michigan | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
| WO2018041248A1 (en) | 2016-09-01 | 2018-03-08 | 北京赛林泰医药技术有限公司 | Bcl-2 selective inhibitor and preparation and use thereof |
| CN106565706B (en) | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | A kind of sulfamide derivative and its application in pharmacy |
| CN106749233B (en) | 2016-11-24 | 2020-04-21 | 中山大学 | Sulfonamide derivatives and application thereof |
| BR112020022092A2 (en) * | 2018-04-29 | 2021-02-02 | Beigene, Ltd. | compounds, method for treating unregulated apoptotic diseases and pharmaceutical composition |
| US20220073513A1 (en) | 2018-12-29 | 2022-03-10 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
-
2019
- 2019-04-29 BR BR112020022092-2A patent/BR112020022092A2/en unknown
- 2019-04-29 CN CN202311185016.XA patent/CN117430601A/en active Pending
- 2019-04-29 CN CN201980029015.1A patent/CN112437772B/en active Active
- 2019-04-29 MX MX2020011495A patent/MX2020011495A/en unknown
- 2019-04-29 SG SG11202009933WA patent/SG11202009933WA/en unknown
- 2019-04-29 CA CA3098348A patent/CA3098348A1/en active Pending
- 2019-04-29 KR KR1020207033817A patent/KR20210005677A/en not_active Application Discontinuation
- 2019-04-29 CN CN202311486964.7A patent/CN117683029A/en active Pending
- 2019-04-29 EP EP19797052.8A patent/EP3788042A4/en active Pending
- 2019-04-29 JP JP2020555218A patent/JP2021521138A/en active Pending
- 2019-04-29 US US17/050,581 patent/US11420968B2/en active Active
- 2019-04-29 WO PCT/CN2019/085001 patent/WO2019210828A1/en unknown
- 2019-04-29 AU AU2019264475A patent/AU2019264475A1/en active Pending
-
2020
- 2020-04-28 TW TW109114185A patent/TW202043217A/en unknown
- 2020-10-29 MX MX2023001689A patent/MX2023001689A/en unknown
-
2022
- 2022-05-23 US US17/750,821 patent/US20220402915A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3788042A4 (en) | 2022-01-26 |
| WO2019210828A1 (en) | 2019-11-07 |
| US11420968B2 (en) | 2022-08-23 |
| CN117683029A (en) | 2024-03-12 |
| CN112437772A (en) | 2021-03-02 |
| KR20210005677A (en) | 2021-01-14 |
| MX2020011495A (en) | 2021-01-15 |
| US20220402915A1 (en) | 2022-12-22 |
| JP2021521138A (en) | 2021-08-26 |
| TW202043217A (en) | 2020-12-01 |
| BR112020022092A2 (en) | 2021-02-02 |
| CN117430601A (en) | 2024-01-23 |
| US20210269433A1 (en) | 2021-09-02 |
| AU2019264475A1 (en) | 2020-11-12 |
| EP3788042A1 (en) | 2021-03-10 |
| CN112437772B (en) | 2023-11-21 |
| MX2023001689A (en) | 2023-02-22 |
| CA3098348A1 (en) | 2019-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202009933WA (en) | Bcl-2 INHIBITORS | |
| IL283639A (en) | Kif18a inhibitors | |
| IL291430A (en) | Mcl-1 inhibitors | |
| FI3672976T3 (en) | Bcl-2 inhibitors | |
| IL269196A (en) | Novel inhibitors | |
| ZA202006327B (en) | Magl inhibitors | |
| IL276813A (en) | Arginase inhibitors | |
| SG11202010914YA (en) | Furin inhibitors | |
| IL277778B (en) | Bcl6 inhibitors | |
| GB201807014D0 (en) | Factor xlla inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| IL289622A (en) | Bcl-2 protein inhibitors | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| EP3600301A4 (en) | Kdm4 inhibitors | |
| IL283309A (en) | Rip1 inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL274550A (en) | Dopamine-b-hydroxylase inhibitors | |
| GB202014309D0 (en) | Refrigerating apparatus | |
| IL279419A (en) | Ccl5 inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201809939D0 (en) | Eastase inhibitor | |
| GB201721465D0 (en) | Inhibitors |